Detailed Information

Atypical Hemolytic Uremic Syndrome Associated With Complement Factor H Autoantibodies and CFHR1/CFHR3 Deficiency

DC Field Value Language
dc.contributor.authorLee, Beom Hee-
dc.contributor.authorKwak, Soo Heon-
dc.contributor.authorShin, Jae Il-
dc.contributor.authorLee, So Hee-
dc.contributor.authorKang, Hee Gyung-
dc.contributor.authorLee, Jae Seung-
dc.contributor.authorChoi, Yong-
dc.contributor.authorCheong, Hae Il-
dc.contributor.authorDragon-Durey, Marie-Agnes-
dc.contributor.authorHa, Il Soo-
dc.contributor.authorChoi, Hyun Jin-
dc.identifier.citationPEDIATRIC RESEARCH; Vol.66 3; 336-340ko_KR
dc.description.abstractAlthough genetic defect of complement factor H (CFH) is a common cause of atypical hemolytic uremic syndrome (aHUS), development of autoantibodies to CFH (CFH-Ab) is also known to be an acquired cause of aHUS. Recently, a correlation between the development of CFH-Ab and the deficiency of the CFH-related proteins, CFHR1 and CFHR3, was identified. In this study, plasma complement profiles were measured and genetic analysis of the CFH, CFI, MCP, CFHR1, and CFHR3 genes were performed in three female patients diagnosed with aHUS with positive CFH-Ab. Acute stage plasmas of all the three patients revealed low C3, low or low-normal CFH antigenic levels, and high titers of CFH-Ab. All the patients also showed complete plasma CFHR1 deficiency and homozygous genomic deletion of CFHR1/CFHR3, but none had CFH, CFI, or MCP mutations. All the patients were treated with plasmapheresis, and two patients required additional immunosuppressive therapy. These patients had a novel subgroup of aHUS characterized by a combination of genetic (a homozygous deletion of CFHR1/CFHR3) and acquired (development of CFH-Ab) factors. Patients with this disease may need intensive immunosuppressive therapy in addition to plasmapheresis. Screening for CFH-Ab and the CFHR1/CFHR3 deficiency should be included in the diagnostic tests for patients with aHUS.ko_KR
dc.description.sponsorshipSupported by a Grant A080588 from the Korea Healthcare technology R&D Project,
Ministry for Health, Welfare and Family Affairs, Republic of Korea and a Grant
06-2008-192-9 from the Seoul National University Hospital.
dc.titleAtypical Hemolytic Uremic Syndrome Associated With Complement Factor H Autoantibodies and CFHR1/CFHR3 Deficiencyko_KR
dc.citation.journaltitlePEDIATRIC RESEARCH-
dc.description.citedreferenceLEQUINTREC M, 2009, AM J TRANSPLANT, V9, P1223-
dc.description.citedreferenceFremeaux-Bacchi V, 2008, BLOOD, V112, P4948, DOI 10.1182/blood-2008-01-133702-
dc.description.citedreferenceKwon T, 2008, NEPHROL DIAL TRANSPL, V23, P2088, DOI 10.1093/ndt/gfn063-
dc.description.citedreferenceJozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876-
dc.description.citedreferenceKavanagh D, 2008, ANNU REV MED, V59, P293, DOI 10.1146/
dc.description.citedreferenceJozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472-
dc.description.citedreferenceSellier-Leclerc AL, 2007, J AM SOC NEPHROL, V18, P2392-
dc.description.citedreferenceZipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041-
dc.description.citedreferencede Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103-
dc.description.citedreferenceVenables JP, 2006, PLOS MED, V3, P1957, DOI 10.1371/journal.pmed.0030431-
dc.description.citedreferenceCaprioli J, 2006, BLOOD, V108, P1267, DOI 10.1182/blood-2005-10-007252-
dc.description.citedreferenceVaziri-Sani F, 2006, KIDNEY INT, V69, P981, DOI 10.1038/
dc.description.citedreferenceHEINEN S, 2006, HUM MUTAT, V27, P292-
dc.description.citedreferenceJozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868-
dc.description.citedreferenceKavanagh D, 2006, BRIT MED BULL, V77-78, P5, DOI 10.1093/bmb/ldl004-
dc.description.citedreferenceLupski JR, 2005, PLOS GENET, V1, P627, DOI 10.1371/journal.pgen.0010049-
dc.description.citedreferenceFremeaux-Bacchi V, 2005, J MED GENET, V42, P852, DOI 10.1136/jmg.2005.030783-
dc.description.citedreferenceDragon-Durey MA, 2005, SPRINGER SEMIN IMMUN, V27, P359, DOI 10.1007/s00281-005-0003-2-
dc.description.citedreferenceJokiranta TS, 2005, AM J PATHOL, V167, P1173-
dc.description.citedreferenceNoris M, 2005, J AM SOC NEPHROL, V16, P1035-
dc.description.citedreferenceEsparza-Gordillo J, 2005, HUM MOL GENET, V14, P703, DOI 10.1093/hmg/ddi066-
dc.description.citedreferenceDragon-Durey MA, 2005, J AM SOC NEPHROL, V16, P555-
dc.description.citedreferenceAtkinson JP, 2005, ANN NY ACAD SCI, V1056, P144, DOI 10.1196/annals.1352.032-
dc.description.citedreferenceCoppo P, 2004, MEDICINE, V83, P233, DOI 10.1097/
dc.description.citedreferenceDragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787-
dc.description.citedreferenceNeumann HPH, 2003, J MED GENET, V40, P676-
dc.description.citedreferenceManuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651-
dc.description.citedreferenceHellwage J, 2002, J IMMUNOL, V169, P6935-
dc.description.citedreferenceMale DA, 2000, MOL IMMUNOL, V37, P41-
dc.description.citedreferenceZipfel PF, 1999, IMMUNOPHARMACOLOGY, V42, P53-
dc.description.citedreferenceKRISTENSEN T, 1986, P NATL ACAD SCI USA, V83, P3963-
dc.description.citedreferenceSCHWARTZ GJ, 1976, PEDIATRICS, V58, P259-
Appears in Collections:
Files in This Item:
There are no files associated with this item.


Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.